Segal Trials plays key role in FDA approval of Cobenfy, a new era in schizophrenia treatment
- Cobenfy, a muscarinic agonist developed by Bristol Myers Squibb, has been approved by the FDA for treating schizophrenia in adults.
- The drug targets muscarinic receptors, reducing psychosis symptoms with fewer metabolic side effects compared to traditional antipsychotics.
- Segal Trials contributed essential data across multiple phases of the EMERGENT program, pivotal to the FDA approval.
- The approval marks a significant advancement in mental health care, offering a new treatment alternative for schizophrenia.
Read more
